Recently, Sotoudeh et al. reported that ANTXR1 was overexpressed in GC and a promising molecular target for both clinical and preclinical assessment for immunotherapy of stomach cancer (Sotoudeh et al., 2019). This evidence concerns the gene ANTXR1 and gastric cancer.